BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Tapping into AI, ML Technology to Facilitate Early Diagnosis of Brain Disorders

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, commenced its three-stage development process with the first phase in 2018 that resulted in the creation of the NeuroCap(TM) and NeuroEEG(TM). “The second phase, currently ongoing, is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency and accuracy of diagnostic analytics provided by the application,” reads a recent article. In the future, the company’s technology will leverage AI and ML technology with an extensive cloud-based database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s. With the market for neurodiagnostic devices expected to expand in tandem with the growth of neurological disorders globally, “Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders.”

To view the full article, visit https://ibn.fm/p8iCR

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork